Apolipoprotein E (APOE) Human Gene Knockout Kit (CRISPR)

CAT#: KN200395BN

APOE - human gene knockout kit via CRISPR, HDR mediated

Functional Cassette: GFP-puro Luciferase-Puro RFP-BSD mBFP-Neo



HDR-mediated knockout kit validation

  See Other Versions

USD 1,657.00

2 Weeks*

Size
    • 1 kit

Product Images

Frequently bought together (3)
pCAS-Scramble, pCas-Guide vector with a scrambled sequence as a negative control (10 µg)
    • 10 ug

USD 450.00


Mouse Monoclonal ApoE4 Antibody (4E4)
    • 100 ul

USD 550.00


APOE (Myc-DDK-tagged)-Human apolipoprotein E (APOE)
    • 10 ug

USD 300.00

Other products for "Apolipoprotein E"

Specifications

Product Data
Format 2 gRNA vectors, 1 mBFP-Neo donor, 1 scramble control
Donor DNA mBFP-Neo
Symbol Apolipoprotein E
Locus ID 348
Components

KN200395G1, Apolipoprotein E gRNA vector 1 in pCas-Guide CRISPR vector, Target Sequence: TCAGGAGAGCTACTCGGGGT

KN200395G2, Apolipoprotein E gRNA vector 2 in pCas-Guide CRISPR vector, Target Sequence: GTAGCTCTCCTGAGACTACC

KN200395BND, donor DNA containing left and right homologous arms and mBFP-Neo functional cassette.

Homologous arm and mBFP-Neo sequences:

pUC vector backbone in gray; Left arm sequence in blue; mBFP-Neo in green; Right arm in violet

GAGATGGGGT TTCACCATGT TGGCCAGGCT GGTCTCAAAC TCCTGACCTT AAGTGATTCG CCCACTGTGG CCTCCCAAAG TGCTGGGATT ACAGGCGTGA GCTACCGCCC CCAGCCCCTC CCATCCCACT TCTGTCCAGC CCCCTAGCCC TACTTTCTTT CTGGGATCCA GGAGTCCAGA TCCCCAGCCC CCTCTCCAGA TTACATTCAT CCAGGCACAG GAAAGGACAG GGTCAGGAAA GGAGGACTCT GGGCGGCAGC CTCCACATTC CCCTTCCACG CTTGGCCCCC AGAATGGAGG AGGGTGTCTG TATTACTGGG CGAGGTGTCC TCCCTTCCTG GGGACTGTGG GGGGTGGTCA AAAGACCTCT ATGCCCCACC TCCTTCCTCC CTCTGCCCTG CTGTGCCTGG GGCAGGGGGA GAACAGCCCA CCTCGTGACT GGGGGCTGGC CCAGCCCGCC CTATCCCTGG GGGAGGGGGC GGGACAGGGG GAGCCCTATA ATTGGACAAG TCTGGGATCC TTGAGTCCTA CTCAGCCCCA GCGGAGGTGA AGGACGTCCT TCCCCAGGAG CCGGTGAGAA GCGCAGTCGG GGGCACGGGG CTGGGCAGCA GAGACGACCC GACCCGCTAG AAGGTGGGGT GGGGAGAGCA GCTGGACTGG GATGTAAGCC ATAGCAGGAC TCCACGAGTT GTCACTATCA TTTATCGAGC ACCTACTGGG TGTCCCCAGT GTCCTCAGAT CTCCATAACT GGGGAGCCAG GGGCAGCGAC ACGGTAGCTA GCCGTCGATT GGAGAACTTT AAAATGAGGA CTGAATTAGC TCATAAATGG AACACGGCGC TTAACTGTGA GGTTGGAGCT TAGAATGTGA AGGGAGAATG AGGAATGCGA GACTGGGACT GAGATGGAAC CGGCGGTGGG GAGGGGGTGG GGGGATGGAA TTTGAACCCC GGGAGAGGAA GATGGAATTT TCTATGGAGG CCGACCTGGG GATGGGGAGA TAAGAGAAGA CCAGGAGGGA GTTAAATAGG GAATGGGTTG GGGGCGGCTT GGTAAATGTG CTGGGATTAG GCTGTTGCAG ATAATGCAAC AAGGCTTGGA AGGCTAACCT GGGGTGAGGC CGGGTTGGGG CCGGGCTGGG GGTGGGAGGA GTCCTCACTG GCGGTTGATT GACAGTTTCT CCTTCCCCAG ACTGGCCAAT

GE100003, scramble sequence in pCas-Guide vector

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.
Reference Data
RefSeq NM_000041, NM_001302688, NM_001302689, NM_001302690, NM_001302691
UniProt ID P02649
Synonyms AD2; APO-E; LDLCQ5; LPG
Summary The protein encoded by this gene is a major apoprotein of the chylomicron. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. This gene maps to chromosome 19 in a cluster with the related apolipoprotein C1 and C2 genes. Mutations in this gene result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. [provided by RefSeq, Jun 2016]

Other Versions

{0} Product Review(s)

0 Product Review(s) Submit review

Be the first one to submit a review

Product Citations

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.